Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Multiple Myeloma Bispecifics Vie For Leadership Based On Safety, Combinability

Janssen Has First Combo Data, With Its Own Darzalex

Executive Summary

Updates at ASH for bispecifics targeting BCMA, GPRC5D and FcRH5 from Regeneron, Janssen, Pfizer, Roche, AbbVie and Harpoon show monotherapy efficacy, initial combination data and potential safety differentiation.

You may also be interested in...



J&J Advances Myeloma Domination Plan With Bispecific Tecvayli Approval

With Darzalex and Carvykti already making J&J a leader in the field, the company has added another dimension to its offering with the first multiple myeloma bispecific antibody therapy.

As CAR-T Therapies Move Into Earlier Lines, Best Uses Begin To Come Into Focus

Cost, logistics and safety could limit use of CAR-T therapies in first- and second-line treatment of hematologic malignancies, but for some patients there are clear benefits over standards of care.

Regeneron Has Strong Showing, But No REGEN-COV Sales Expected In First Half

Dupixent sales grew by more than 50% as Eylea and REGEN-COV also drove sales growth, though the antiviral advantage will vanish due to the FDA restricting its use.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC145585

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel